Regulation of angiotensinogen production by angiotensin II analogues

Détails

ID Serval
serval:BIB_BCC7C58EFF5D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Regulation of angiotensinogen production by angiotensin II analogues
Périodique
Journal of Hypertension. Supplement
Auteur(s)
Darby  I. A., Coezy  E. D., Mizrahi  J., Cantau  B., Donnadieu  M. H., Nussberger  J., Corvol  P.
ISSN
0952-1178 (Print)
Statut éditorial
Publié
Date de publication
12/1988
Volume
6
Numéro
4
Pages
S446-8
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Dec
Résumé
Specific binding sites for angiotensin II (Ang II) were identified in a human hepatoma cell line, HepG2. Binding of [125I]-Sar1 Ang II to these cells showed a high-affinity site with a Kd of 2.4 +/- 0.2 nmol/l. This specific binding was not changed during the cell cycle and showed no alteration after 24 h of treatment with Sar1-Ang II (10(-8) mol/l). Exposure of HepG2 cells to the Ang II agonist Sar1-Ang II caused a dose-dependent decrease in angiotensinogen production. The maximal inhibitory effect was at a dose of 10(-6) mol/l Sar1-Ang II which elicited 67% inhibition of angiotensinogen production after 24 h (control: 2.015 +/- 0.5 micrograms angiotensinogen/mg DNA; Sar1-Ang II 10(-6) mol/l: 0.68 +/- 0.03 micrograms angiotensinogen/mg DNA). Fifty per cent inhibition was obtained at a dose of 10(-9) mol/l Sar1-Ang II. Angiotensin II had a less marked effect, showing maximal inhibition of 40%. This study shows that the HepG2 cells possess specific Ang II binding sites and that Ang II analogues induce a dose-dependent inhibition of angiotensinogen production in cell culture.
Mots-clé
Angiotensin II/*analogs & derivatives/pharmacology Angiotensinogen/*biosynthesis Cell Line Humans Liver/metabolism
Pubmed
Web of science
Création de la notice
05/03/2008 17:41
Dernière modification de la notice
03/03/2018 20:57
Données d'usage